trial

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

NCTId NCT05351736
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 10 (estimated)
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Primary completion 2024-01-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
10 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-01-26
Primary completion
2024-01-28
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoLead Sponsor

Investigators

1
Paolo Brambilla, ProfessorPrincipal Investigator

Sites

1 total
Milan, Italy

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE4
Primary Completion Date
2024-01-28
Status
UNKNOWN
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Paolo Brambilla, Professor
person